The International “Chemotherapy-Induced Myelosuppression Treatment Market” is growing at rapid rate with CAGR CAGR of around 3.6% between 2018 and 2025.
The global chemotherapy-induced myelosuppression treatment market is divided into three categories based on the indication: anaemia, neutropenia, and thrombocytopenia. In 2018, the neutropenia indication segment led the market, and it is expected to continue to do so over the projection period. This is due to the fact that neutropenia is the most common side effect of myelosuppression therapy. Because the severity and complications of neutropenia can be fatal, more emphasis is paid to avoiding neutropenia after myelosuppression treatment, resulting in a large share.
Over the predicted period, the thrombocytopenia segment will expand the most. The market is divided into thrombopoietic agents, erythropoietin boosting agents, iron supplements, growth factors, and others based on pharmacological class. The growth factors drug class segment dominated the market in 2018. The erythropoietin stimulating agents segment, on the other hand, will grow at the fastest rate over the projection period. The global market is divided into injectable and oral segments based on the route of administration. In 2018, the injectable administration route segment dominated the market. This is due to the fact that, as compared to oral medications, they have a higher therapeutic availability.
Retail pharmacies, hospital pharmacies, and internet pharmacies make up the distribution channel sector of the chemotherapy-induced myelosuppression treatment market. Retail pharmacies dominated the market with the highest revenue share among all distribution channels in 2018. In the coming years, online pharmacies are likely to increase rapidly.The distribution channel segment of the chemotherapy-induced myelosuppression treatment market is categorized into retail pharmacies, hospital pharmacies and online pharmacies. Among all distribution channels, retail pharmacies dominated the market in 2018 with largest revenue share. Online pharmacies are expected to witness rapid growth in the years to come.
Global demand for Chemotherapy-induced myelosuppression treatment market was valued at approximately USD 13.81 billion in 2018, and is expected to generate revenue of around USD 17.65 billion by end of 2025
In 2018, North America accounted for the biggest revenue share of the global market for chemotherapy-induced myelosuppression treatments. Strong commercial sales, advantageous reimbursement rules, a huge cancer patient pool, increased awareness, and the presence of significant companies in this region all contribute to this large share. In terms of revenue, Europe was the second-largest regional market. Major factors that drive market expansion in this region include the availability of improved infrastructure, rising cancer prevalence, and rising awareness.
Chemotherapy-induced myelosuppression treatment is expected to be a fast developing regional market in Asia Pacific. Major reasons contributing to the region’s rapid growth include rising cancer prevalence and senior population, economic development, improved healthcare infrastructure, rising disposable income and healthcare spending, and rising awareness. Over the predicted period, Latin America is expected to increase at a moderate pace. In the future years, the Middle East and Africa will have sluggish growth.
Major Competitors in chemotherapy-induced myelosuppression treatment market are Teva Pharmaceutical Industries Ltd., Amgen Inc., Janssen Global Services, LLC, Pfizer Inc., Mylan NV, Mission Pharmacal Company, Myelo Therapeutics GmbH, Dova Pharmaceuticals, Partner Therapeutics, Inc. and Novartis AG among others among others.
Market By Secondary Research
Press releases, yearly reviews, non-profit organisations, business institutions, government agencies and customs data, and many more secondary assets are available. The use of massive secondary assets, directories, and databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual opinions, BIS Statistics, and ICIS; agency house files; CAS (American Chemical Society); investor presentations; and SEC filings of organisations are all examined in this study. Secondary research was performed to find and obtain information for a large-scale, technical, market-oriented, and business examination of the Pure Nicotine market.
It was widely used to get critical information on the top agencies, market class and segmentation based on lowest-to-highest level organisation advancements, and major market and technological trends.
TOC: Extracts from the Market for Chemotherapy-Induced Myelosuppression Treatment
- Overview of the Report
- Global Development Trends
- Key Players’ Competitive Landscape
- North America Data by Type Data by Application Market Research
- Europe Market Research
- Asia-Pacific Market Research
- Market Research in Latin America
- Africa and the Middle East Market Research
- Profiles of Key Players Analysts who do market research Viewpoints/Conclusions
Analysis of the Covid-19 scenario:
The Covid outbreak has put cancer patients in significant peril all around the world. Concerned about their inadequate immunity, top hospitals and research institutions are encouraging cancer patients to stay at home until Covid infections are eradicated. Many cancer patients’ treatment plans have been thrown off by the postponement of surgery, radiation, and chemotherapy sessions. Patients undergoing cancer therapy may have a low level of immunity, making them more susceptible to infection. And if it does, the patient will die quickly. As a result, doctors are taking all necessary precautions to keep kids safe — at least from Covid. As a result of decreased bone marrow activity, myelosuppression causes a decrease in blood cell formation.
This may result in a decrease in all types of blood cells, including red blood cells (RBCs), white blood cells (WBCs), platelets, or any other type of blood cell. As a result, cancer patients’ immunity must be boosted by providing them with the necessary treatment. As a result, the market is stable, but there may be some inconvenience due to low supply and manufacturing during the pandemic.